Q-omics provides the consensus-scored NIFKP6 profile across patient tissues and cancer cell-line models. NIFKP6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NIFKP6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, NIFKP6 RNA expression shows 9,038 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where NIFKP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIFKP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIFKP6 survival associations across molecular data types. NIFKP6 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIFKP6 RNA expression–survival associations across cancer types. High NIFKP6 expression shows unfavorable associations in KIRP, KIRC, ACC and LIHC, but favorable associations in COAD and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for NIFKP6 RNA expression.
This table summarizes NIFKP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NIFKP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIFKP6 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, BLCA, COAD and KIRC. The HNSC box plot shows higher NIFKP6 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .001).
This table shows molecular features associated with NIFKP6 in patient tissues and cancer cell lines. In patient samples, NIFKP6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
